Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Anand Kiran Parikh is President and CEO at Faeth Therapeutics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Nov 4, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
2
Companies involved
1
Faeth TherapeuticsFTH
2 disclosures · Nov 2026
Oct 30, 2026100Kdisclosed Nov 4
DetailsOfficial recordOct 30, 2026100Kdisclosed Nov 4
DetailsOfficial recordOn the latest SEC Form 4, dated Oct 30, 2026, Anand Kiran Parikh reported holding 817,699 shares of Faeth Therapeutics (FTH), of which 100,000 are held indirectly. At the last close of $10 on Nov 13, 2026, that is about $8.2M. This is the stake disclosed in filings, not a net worth.
As of the latest filing on , Anand Kiran Parikh reported holding 817,699 shares of Faeth Therapeutics (FTH), worth about $8.2M at the last close of $10 (Nov 13, 2026): 717,699 held directly and 100,000 through a see footnote.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Faeth Therapeutics FTH | 817,699 | 718K direct · 100K see footnote | $10 | $8.2M | Oct 30, 2026 |
Is this Anand Kiran Parikh’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.